February 20, 2020
Dear Advocates,
In case you missed them, this round-up includes links to updates on PrEP and the vaccine field, advances on pioneering work using human-centered design to inform prevention programs, and essential resources for advocates focused on PEPFAR’s COP planning process, opportunities to engage on the issues of next generation trial design and resources that arm you for smart advocacy in 2020 at large.
Dive Into Next Generation Trial Design at CROI
Join our participatory dialogue on next generation trial design! Advocates, researchers and community members will discuss what’s on the table for next-generation HIV prevention trials, including design, regulatory and ethical considerations and mechanisms for community engagement. Co-hosted by AVAC,
The Fenway Institute at Fenway Health and
The Forum for Collaborative Research, on the sidelines of the
Conference on Retroviruses and Opportunistic Infections (CROI).
- Monday, March 9, 2020 6:30-9:00 PM ET
The Fenway Institute, 1340 Boylston St., Boston.
Register here!
The latest Updates on HVTN 702
On Feb 3, HVTN 702 trial leaders
announced that vaccinations would be stopped early because the vaccine candidate did not prevent HIV. Importantly, there were no safety concerns. To help advocates understand the results and the implications for the future of HIV vaccine development check out:
New Findings from Breaking the Cycle of Transmission
AVAC’s
Anabel Gomez and
Shawn Malone report on their research exploring the factors that influence decision-making among young women who are at high risk of HIV. Check out the chapter they authored,
Understanding HIV prevention in high-risk adolescent girls and young women in two South African provinces, in the
22nd edition of The South African Health Review (SAHR) 2019-12-31. And watch
this recorded webinar discussion, featuring this research—one in a monthly series on PrEP rollout produced by the
PrEP Learning Network. These research findings are part of the
Breaking the Cycle of Transmission project, conducted under AVAC and
CHAI’s
HIV Prevention Market Manager (PMM) project.
Tools for Advocates Engaging with PEPFAR
This
FAQ on index testing—a testing approach that tracks the contacts of people who test positive for HIV—provides background on the issue and frames advocacy priorities. While index testing holds potential benefits if ethically done, it’s being implemented now in ways that cause harm and undermine human rights. Changes must be made to protect individuals and foster community trust in their healthcare system.
New factsheets on PEPFAR’s performance and funding by country are now available. They are produced by
amfAR as part of our
Coalition to build Momentum, Activism, Solidarity & Strategy Africa (COMPASS Africa), and found on amfAR’s
PEPFAR Monitoring, Evaluation and Reporting Database! You’ll find details on funding by program area, testing program results, key population size estimates and more. Be sure to search by country and find a downloadable fact sheet on the upper right of each country page.
How Does PrEPWatch Work for You?
Calling all PrEPWatch users! Help us understand how the website is being used, what tools and resources you find most useful, and how we can improve with
this 3-minute survey. Your responses are highly valued and will be kept confidential.
Advocacy Priorities in 2020
The latest episode of AVAC’s podcast, Px Pulse, lays out AVAC’s view of the state of the field in light of certain failure to meet UNAIDS
Fast-Track targets by the 2020 deadline. In this episode of
Px Pulse,
AVAC’s Emily Bass and lead author of our report
Now What? talks about AVAC’s blueprint for course correcting. Tune in to learn more!
Best,
AVAC
